0000947871-23-000778.txt : 20230724 0000947871-23-000778.hdr.sgml : 20230724 20230724164042 ACCESSION NUMBER: 0000947871-23-000778 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230720 FILED AS OF DATE: 20230724 DATE AS OF CHANGE: 20230724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gupta Rishi CENTRAL INDEX KEY: 0001537370 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41747 FILM NUMBER: 231105501 MAIL ADDRESS: STREET 1: C/O CHEMOCENTRYX, INC. STREET 2: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turnstone Biologics Corp. CENTRAL INDEX KEY: 0001764974 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832909368 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 920 BROADWAY STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 347-897-5988 MAIL ADDRESS: STREET 1: 920 BROADWAY STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 4 1 ownership.xml X0508 4 2023-07-20 0 0001764974 Turnstone Biologics Corp. TSBX 0001537370 Gupta Rishi C/O TURNSTONE BIOLOGICS CORP. 9310 ATHENA CIRCLE, SUITE 300 LA JOLLA CA 92037 1 0 1 0 0 Common Stock 2023-07-20 4 C 0 2682599 A 2682599 I See Footnote Common Stock 2023-07-20 4 P 0 416666 12 A 3099265 I See Footnote Series B-1 Preferred Stock 2023-07-20 4 C 0 937372 D Common Stock 937372 0 I See Footnotes Series B-2 Preferred Stock 2023-07-20 4 C 0 1249829 D Common Stock 1249829 0 I See Footnotes Series C Preferred Stock 2023-07-20 4 C 0 266240 D Common Stock 266240 0 I See Footnotes Series D Preferred Stock 2023-07-20 4 C 0 229158 D Common Stock 229158 0 I See Footnotes Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI. Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Rishi Gupta 2023-07-24